Cincinnati Section, The American Chemical Society January Monthly Meeting - Monday, January 31, 2000 Embassy Suites Hotel, Blue Ash

Program
 

5:00 - 5:45 pm	Chemical Information Discussion Group Bartow Culp, Chemistry Librarian Purdue University
5:30-6:00 pm	Registration ($12) and Social; when possible, please pay with exact change or by check
6:00-7:00 pm	Featured Speaker, Douglas Axelrod New Therapeutics for Osteoporosis
7:00 - 8:00 pm	Mixer with Hors d’ oeuvres and Open Bar
7:45 - 8:30 pm	Iota Sigma Pi Discussion Group  Elizabeth Piocos, The Procter and Gamble Company What the Women Chemists Committee (WCC) Can Bring to the ACS

The Embassy Suites restaurant will be available for dining. Please make reservations with them directly if you would like to stay for dinner. Phone: 733-8900

Reception Reservations:

E-mail your reservations to cintacs.im@pg.com Include your name (complete with correct spelling), phone number and affiliation. Please specify if this is your first Cincinnati ACS meeting when making your reservation. All reservations must be received by noon, Wednesday, Jan. 26, 2000. If you have any difficulties, please call Debbie Lewis at (513) 622-3423. As a reminder, if you decide you must miss a meeting after you have made reservations, please call to cancel. If you do not cancel, the Section will have to charge you because it will have been charged by the hotel. Payment will be received at the door. Guests are always welcome; emeritus, unemployed, new, and student members are half price.

Directions to Embassy Suites Hotel, 4554 Lake Forest Dr., Blue Ash

From I-71, take Exit 15 (Pfeiffer Road), head west on Pfeiffer Road two blocks to Reed Hartman Highway. Turn right (north) on Reed Hartman, turn left on to Lake Forest Dr.

From I-275, take the Reed Hartman Exit, head south on Reed Hartman about two miles, take a right onto Lake Forest Dr.

Abstract

With an explosion of new agents available for the prevention and treatment of osteoporosis, it may be appropriate to return to the needs of the patient in the near term and to strategize toward the most useful next steps in osteoporosis therapeutics.

First, the issue of true "prevention" must be taken more seriously. At present, beyond the usual prescription of supplemental calcium, vitamin D, and exercise, estrogen or Raloxifene, the first "selective estrogen receptor modulator (SERM)" approved for this indication, are offered to postmenopausal women. Other antiresorptive therapies (vide infra) are offered to those women who cannot or should not take estrogens and to men, an underappreciated population at risk. This approach discloses the enormous gap in our understanding of the pathogenesis of estrogen deprivation and other osteoporoses, stunting efforts at discovering new therapies which prevent osteoporosis by interfering with proximal disordered process(es) without resorting to estrogens or unfocused antiresorptive therapies. Although efforts will continue in identifying those at highest risk for bone loss, specific genetic predispositions and in-life risks are likely to contribute too small an individual risk to justify empirical therapy on the basis of these risks alone.

Second, our current therapeutics rely very heavily on antiresorptive actions at the bone. By inhibiting bone activation frequency, resorption depth, or both, bone microarchitecture can be spared and bone formation can outpace resorption, at least for a while, leading to modest increases in bone mass and stabilization of architecture. The newly available bisphosphonates, in addition to new formulations of calcitonin, additional formulations of estrogen, estrogen/gestagen combinations, and more SERMs will likely saturate the antiresorptive needs of this population, leading to product differentiation only by secondary matters of effects at secondary target tissues, patient tolerance, price, and marketing strategy.

Unfortunately, this "one size fits all" approach to the treatment of osteoporosis leaves out important pathophysiologic issues along with important therapeutic opportunities. At present, purely antiresorptive therapies may stabilize microarchitecture and add a modest amount of new bone, but cannot truly repair the "template" of cancellous bone architecture, nor add sufficient bone to normalize the skeletal fragility of most patients with established osteoporosis. The current ability of antiresorptives to reduce fracture rates by 50 percent belies the high residual absolute rate of fracture in those with established osteoporosis and the impact of that residual risk on their lives.

These facts highlight the need for agents which generate new bone in the right places, of which fluoride and parathyroid hormone are the only current opportunities. Limitations in these agents open the window for new generations of anabolic agents in the future. These coming therapies will require new strategies in clinical design, regulatory approaches, and population selection, all of which will be discussed.

About The Speaker

Dr. Axelrod was raised in San Antonio, Texas, the first born son of Brooklyn escapees. He went to college at Beloit College in Beloit, Wisconsin, where they had seasons. He earned a Ph.D. in Bert O’Malley’s Department of Cell Biology at Baylor College of Medicine, studying lysosomal function in skeletal muscle. He earned his M.D. at the same institution, where he specialized in Internal Medicine with subspecialty Fellowship in Endocrinology, spending his third Fellowship year as Visiting Scientist at the M.D. Anderson Tumor Institute. In 1991, he joined Procter & Gamble Pharmaceuticals in Norwich, New York, as a medical monitor on the risedronate osteoporosis project. Later that year, he became Medical Director of that program.

In 1992, he created the Clinical Bone and Mineral Research Group, which was responsible for the worldwide medical development of all bone products for Procter & Gamble Pharmaceuticals, including bisphosphonates and estrogens. This organization was responsible for the approvals of Didronel for osteoporosis in many countries worldwide, and for the approval of risedronate for the treatment of Paget’s Disease of Bone. Worldwide product licensing applications for risedronate in the treatment and prevention of osteoporosis are under review worldwide.

In 1997, he moved to the Drug Discovery Department of P&GP, and directed the drug discovery groups in Bone, Arthritis, Infectious Disease, and High Throughput Screening.

In September, 1999, he was appointed Director, Discovery Projects and Biological Sciences, Procter & Gamble Pharmaceuticals.

His avocations include Zen, jazz drumming, and high end audio.

The Chemical Information Discussion Group is pleased to announce that Bartow Culp, Chemistry Librarian, Purdue University, will be leading the discussion at the January meeting.

Abstract

The increase in the number of electronic resources in chemistry in the last decade has been dramatic. Specialized data sources like Beilstein, the Web of Science, and Internet sites such as ChemWeb have successfully challenged Chemical Abstracts Service (CAS)in the market place of chemical information. CAS has responded to these challenges by introducing a variety of new software tools such as STNEasy, SciFinder, and STNWeb, which are intended to facilitate the use of its only real product, Chemical Abstracts. How do these new CAS search tools differ among themselves, and what are their various strengths and weaknesses? What are the main content differences between CAS and its new competitors? The focus of the discussion session will center on these questions, which are vital to anyone conducting chemical research today.

About the Speaker

Bartow Culp has spent about equal time as a Townie and a Gownie in his career as a chemist and librarian. After receiving his B.S. in Chemistry at the University of South Carolina, he continued his studies at the University of Delaware with Dr. James A. Moore, where he received a Ph.D. in Organic Chemistry. After spending 9 years in Academe, he joined the Technical Information Service of the 3M in St. Paul, MN, where he specialized in chemical database construction and information retrieval. He jumped back over the academic wall in 1995 when he became the Chemistry Librarian at Purdue University in West Lafayette, IN.

Back to Index

Formatted and uploaded 05 January 00 by cinacs@www.che.uc.edu